MELA Sciences, Inc. Presents New Data That Reinforces The Importance Of MelaFind® As A Diagnostic Tool At AAD Meeting

   MELA Sciences, Inc. Presents New Data That Reinforces The Importance Of
                MelaFind® As A Diagnostic Tool At AAD Meeting

Data Shows that MelaFind® Significantly Improves Melanoma Detection Rates of
Resident Dermatologists

PR Newswire

IRVINGTON, N.Y., March 18, 2013

IRVINGTON, N.Y., March 18, 2013 /PRNewswire/ -- Research presented by MELA
Sciences, Inc. (NASDAQ: MELA) at the 71^st Annual Meeting of the American
Academy of Dermatology (AAD) shows that MelaFind® can increase the melanoma
detection rates of resident dermatologists when deciding to biopsy melanoma at
its most curable stage. The data offers new insight into the importance of
skin checks appropriately assisted with MelaFind®, as the rates of melanoma
continue to rise in the United States.

(Logo: )

The study, led by Drs. Jane A. Yoo and Darrell S. Rigel, asked 121 resident
dermatologists to evaluate 24 pigmented lesions that had previously been
analyzed by MelaFind®. Biopsy performance results were compared before and
after using the MelaFind® "High" or "Low" Disorganization score. Prior to
factoring in results from MelaFind®, dermatology residents' biopsy sensitivity
was 57%. After reviewing MelaFind® results, sensitivity improved to 77%. The
results, combined with data from a similar study of attending dermatologists,
showed that utilizing MelaFind® can significantly improve the melanoma
detection rates of dermatologists at any experience level.

Skin cancer rates continue to rise, while many other cancer rates decline.^1
"Only 24% of American adults have had a skin check with a dermatologist.^2 We
want to increase those numbers to help combat melanoma, which has reached
epidemic proportions, with one American dying every hour,^3" said Dr. Joseph
Gulfo, President and CEO of MELA Sciences, Inc. "The data presented at AAD
reinforces the importance of MelaFind® and how the tool helps dermatologists
detect melanoma at its most curable stage."

"The data demonstrates that MelaFind® increases the performance of
dermatologists in their decision whether to biopsy melanoma at its most
curable stage," said Darrell S. Rigel, MD, Clinical Professor of Dermatology,
New York University. "MelaFind® continues to prove itself to be a worthy
diagnostic tool for dermatologists to implement during skin cancer checks."

MELA Sciences, Inc. is the pioneer company that developed MelaFind®, the first
and only FDA-approved diagnostic tool to detect melanoma at its most curable
stage. MelaFind® sees 2.5 mm under the skin and uses multi-spectral light
technology to provide dermatologists with additional information of a "High"
or "Low" Disorganization score when deciding which ambiguous moles to biopsy
during skin examinations. In the MelaFind® Pivotal Trial, which was the
largest positive prospective clinical study ever conducted in melanoma
detection, MelaFind® detected 98.3% of the melanomas.

This data and other information on MelaFind® was presented during 10 podium
talks during AAD, the topics of which included skin cancer, melanoma, new
diagnostic tools in the clinical diagnosis and management of melanoma, total
body skin checks, and detection of melanoma at its most curable stage. At AAD,
more than 650 dermatologists engaged directly to learn more about MelaFind®
for their practices; 350 of which received live, in-depth demonstrations.

About MELA Sciences, Inc.
MELA Sciences, Inc. is a medical device company focused on the
commercialization of its flagship product, MelaFind^®, and its further design
and development. MelaFind is a non-invasive tool to provide additional
information to dermatologists during melanoma skin examinations. The device
uses light from visible to near-infrared wavelengths to evaluate skin lesions
up to 2.5 mm beneath the skin. The device provides information on a lesion's
level of morphologic disorganization to provide additional objective
information that may be used by dermatologists in the biopsy decision-making
process. MelaFind has been approved by the US Food and Drug Administration for
use in the US. In addition, MelaFind has received CE Mark approval and is
approved for use in the European Union.

For more information on MELA Sciences, Inc., visit 

Safe Harbor:
This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at and

^1 Facts and Figures Report: Declines in Cancer Deaths Reach
Accessed January 17, 2013.
^2 Harris Interactive on behalf of MELA Sciences, Inc., January 2013; among
2,109 U.S. adults (aged 18 and over)
^3 American Cancer Society. Cancer Facts & Figures 2013.
Accessed January 31, 2013.

SOURCE MELA Sciences, Inc.

Contact: For Investors, Lynn Pieper, Westwicke Partners, +1-415-202-5678; or
For Media, Erica Sperling, Rpr Marketing Communications, +1-212-317-1462,
Press spacebar to pause and continue. Press esc to stop.